Methods A multidisciplinary working group drafted a management algorithm for advanced
urothelial carcinoma using “consensus development conference” methodology. A targeted …

Background and objective We assessed the safety of atezolizumab in unselected patients
(including understudied populations typically excluded from clinical trials) with pretreated …

The most prevalent pathological subtype of bladder and upper urinary tract malignancy is
urothelial carcinoma (UC). Traditional therapies mainly include surgical resection …

Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death
protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial …

Metastatic liver tumors have presented challenges with the use of checkpoint inhibitors
(CPIs), with only limited success. We hypothesize that regional delivery (RD) of CPIs can …

Background Immune checkpoint inhibitors are increasingly important in the treatment
algorithm for locally advanced and metastatic bladder cancer. Numerous ongoing studies …

Objectives Population-adjusted comparisons of progression-free survival (PFS) from single-
arm trials of cancer treatments can be derived using matching-adjusted indirect comparisons …

Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic
chemotherapy regimens have not produced optimal long-term outcomes, and many …

Background Programmed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor
activity in patients with platinum-resistant urothelial cancer (UC). However, the reliability and …

Immunotherapy, the 5th pillar of cancer care after surgery, radiotherapy, cytotoxic
chemotherapy, and precision therapy (molecular targeted therapy), is revolutionizing the …